ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 2986

Trends and Determinants of Osteoporosis Prevention and Management in Patients with Rheumatoid Arthritis Compared to Osteoarthritis

Gulsen Ozen1,2, Diane L. Kamen3, Ted R Mikuls2, Frederick Wolfe4 and Kaleb Michaud2,4, 1Rheumatology, Marmara University Faculty of Medicine, Istanbul, Turkey, 2Rheumatology, University of Nebraska Medical Center, Omaha, NE, 3Medicine/Rheumatology & Immunology, Medical University of South Carolina, Charleston, SC, 4National Data Bank for Rheumatic Diseases, Wichita, KS

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Anti-resorptives, Bone density, Epidemiologic methods, Osteoporosis and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 15, 2016

Session Title: Plenary Session III: Discovery 2016

Session Type: ACR Plenary Session

Session Time: 11:00AM-12:30PM

Background/Purpose: Despite more aggressive treatment strategies and new biologic DMARDs, the prevalence of osteoporosis (OP) leading to fracture in RA remains high. It is unknown whether these treatment changes and release of the 2010 ACR glucocorticoid (GC) induced OP (GIOP) guideline changed physicians’ OP management practices. To evaluate this, we assessed the frequency, trends, and predictors of OP management care in patients with RA compared with OA in the US.

Methods: Patients studied had RA or OA with ≥1 year participation from 2003 through 2014 in the National Data Bank for Rheumatic Diseases. OP management care was defined as either having a bone mineral density (BMD) test or treatment with any anti-OP medications (excluding calcium or vitamin D) in the prior 6 months. Calendar years were evaluated to detect trends for outcome, with 2003 as reference period. Andersen-Gill formulation of Cox proportional hazards models were used to determine adjusted trends of and factors associated with OP management care.

Results: During a median (IQR) followup of 5.5 (2.3-9.0) years in 11,669 RA and 2,829 OA patients, the frequencies of BMD testing were 57% vs. 54% and treatment with any anti-OP medication 44% vs. 42%. Only ~50% of RA and OA patients with prior fragility fractures or long-term GC exposure were on anti-OP treatment. In multivariable analysis, RA patients were 12% more likely to have OP management care compared to OA patients. Factors significantly associated with having OP management care in RA patients were older age, postmenopausal status, prior fragility fracture or diagnosis of OP, GC exposure ≥3 months, treatment with any biologic, and rheumatology care (Table). Cox models showed stable OP management trends between 2003 and 2009, with a significant downward trend after 2009 without any improvement in GC-exposed patients after the release of the 2010 ACR GIOP guideline (Figure). The same downward trend was also observed in long-term GC exposed by bisphosphonate-nonexposed RA patients.

Conclusion: The application of OP management care is slightly higher in RA patients compared to OA, but the frequency of such care in patients at high risk for fracture remains suboptimal. Despite the availability of advanced treatments, the care for OP has not been improving, which may be due to both patient (unwillingness to take more drugs, cost) and physician barriers (lack of time, and focusing more on disease activity and other comorbid conditions). To reduce the morbidity and mortality burden of OP fractures, clarification of the reasons for suboptimal management and effective interventions are needed.    

Table. Potential predictors for both types of osteoporosis management care in patients with rheumatoid arthritis and osteoarthritis

 

  Variables

OP management care, HR (95% CI)

RA patients,

N=11,669

OA patients,

N=2,829

Age groups

 

 

<40 years (referent)

1.0

1.0

40-50 years

1.70 (1.38-2.09)

1.67 (0.57-4.87)

51-64 years

2.22 (1.78-2.78)

1.80 (0.61-5.36)

≥65 years

2.59 (2.07-3.28)

1.72 (0.57-5.12)

Gender

 

 

     Female

Premenopausal (referent)

Postmenopausal

 

1.0

1.62 (1.37-1.92)

 

1.0

2.71 (1.49-4.91)

    Male

0.59 (0.49-0.72)

0.65 (0.35-1.23)

Education level

1.03 (1.01-1.05)

1.05 (1.01-1.09)

No insurance

0.66 (0.50-0.86)

0.96 (0.53-1.73)

Residency in a rural area

0.88 (0.81-0.96)

0.92 (0.75-1.11)

Primary physician, rheumatologist

1.43 (1.26-1.63)

1.19 (1.00-1.41)

Vaccination for influenza

1.11 (1.03-1.20)

1.20 (1.01-1.43)

BMI in categories

 

 

<18.5 kg/m2

1.14 (0.89-1.45)

0.83 (0.26-2.64)

18.5-24.9 kg/m2 (referent)

1.0

1.0

25.0-29.9 kg/m2

0.87 (0.79-0.96)

0. 79 (0.64-0.98)

30.0-39.9 kg/m2

0.80 (0.73-0.89)

0.68 (0.55-0.84)

≥40 kg/m2

0.56 (0.47-0.67)

0.55 (0.40-0.76)

HAQ

1.05 (0.99-1.11)

0.89 (0.78-1.01)

Glucocorticoid use

 

 

Never-used (referent)

1.0

1.0

<3 months

1.12 (0.96-1.31)

0.90 (0.68-1.19)

3-12 months

1.24 (1.09-1.40)

1.24 (0.91-1.68)

>12 months

1.38 (1.26-1.51)

1.72 (1.32-2.22)

Use of DMARDs

 

 

MTX monotherapy (referent)

1.0

–

Any TNFi

1.21 (1.08-1.36)

–

Non-TNFi biologics

1.34 (1.09-1.65)

–

Any others

1.15 (1.03-1.29)

–

Prior fragility fracture

1.10 (1.00-1.22)

1.22 (0.98-1.52)

Prior diagnosis of OP

1.52 (1.37-1.67)

1.35 (1.35-1.65)

*Other covariates included in the model, ethnicity, disease duration, Rheumatic Disease Comorbidity Index, smoking status, were not significantly associated with OP care. The model also included the each calendar from 2003 to 2014.

 

 


Disclosure: G. Ozen, None; D. L. Kamen, None; T. R. Mikuls, None; F. Wolfe, None; K. Michaud, None.

To cite this abstract in AMA style:

Ozen G, Kamen DL, Mikuls TR, Wolfe F, Michaud K. Trends and Determinants of Osteoporosis Prevention and Management in Patients with Rheumatoid Arthritis Compared to Osteoarthritis [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/trends-and-determinants-of-osteoporosis-prevention-and-management-in-patients-with-rheumatoid-arthritis-compared-to-osteoarthritis/. Accessed June 29, 2022.
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/trends-and-determinants-of-osteoporosis-prevention-and-management-in-patients-with-rheumatoid-arthritis-compared-to-osteoarthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2022 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies